Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1595-1603

  Shoaf, Susan E ^a   Ryul Kim, Seong ^b   Bricmont, Patricia ^a   Mallikaarjun, Suresh ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bridging; Food effect; Pharmacodynamics; Pharmacokinetics; Tolvaptan

Indexed keywords

TOLVAPTAN;

ADULT; ADVERSE DRUG REACTION; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CANNULATION SITE REACTION; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; FAINTNESS; FATIGUE; FLUID BALANCE; HUMAN; HUMAN EXPERIMENT; JAPANESE; LABORATORY TEST; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE VOLUME; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; CROSS-OVER STUDIES; DIURETICS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; URINE; YOUNG ADULT;

EID: 84871306932     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1295-5     Document Type: Article

References (18)

1. Yasuda SU, Zhang L, Huang SM (2008) The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84(3):417-423. doi:10.1038/ clpt.2008.141
2. Fukunaga S, Kusama M, Arnold FL, Ono S (2011) Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol 51(8):1237-1240. doi:10.1177/0091270010381500
3. Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44(10):1083- 1105. doi:10.1177/0091270004268128
4. Johnson JA (2000) Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 38(2):53- 60
5. Chen ML (2006) Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 45(10):957-964
6. Uyama Y, Shibata T, Nagai N, Hanaoka H, Toyoshima S, Mori K (2005) Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther 78(2):102-113. doi:10.1016/j.clpt.2005.04.001
7. Ichimaru K, Toyoshima S, Uyama Y (2010) Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clin Pharmacol Ther 87(3):362-366. doi:10.1038/clpt.2009.285
8. Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, Smith RL (2007) Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res 24(6):1118- 1130. doi:10.1007/s11095-007-9236-1
9. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287(3):860-867
10. King LS, Agre P (1996) Pathophysiology of the aquaporin water channels. Annu Rev Physiol 58:619-648. doi:10.1146/ annurev.ph.58.030196.003155
11. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S (2007) Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 47(12):1498-1507. doi:10.1177/ 0091270007307877
12. Fried LF, Palevsky PM (1997) Hyponatremia and hypernatremia. Med Clin North Am 81(3):585-609
13. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies. CDER, Silver Spring, pp 1-12
14. Jones B, Kenward MG (1989) Design and analysis of cross-over trials. Chapman and Hall, London
15. Jusko WJ (1992) Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Jusko WJ, Schentag JJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, p 1202
16. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2002) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. CDER, Silver Spring, pp 1-23
17. Dangi YS, Soni ML, Namdeo KP (2010) Highly variable drugs: Bioequivalence requirement and regulatory perspectives. J Curr Pharm Res 3:24-8
18. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C (2006) Tolvaptan, a selective oral vasopressin V2- receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099- 2112. doi:10.1056/NEJMoa065181